Acurx Pharmaceuticals (ACXP)
(Delayed Data from NSDQ)
$2.15 USD
+0.02 (0.94%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $2.15 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth F Momentum F VGM
Price, Consensus and EPS Surprise
ACXP 2.15 +0.02(0.94%)
Will ACXP be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for ACXP based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Other News for ACXP
Buy Rating Affirmed for Acurx Pharmaceuticals Amid Positive Phase 2b Results and Strategic Pathway to Phase 3 Trials
Acurx's ibezapolstat shows positive results in CDI and Anthrax
Acurx Announces Additional Ibezapolstat Ph2b Results in CDI as well as Anthrax (B. anthracis) Susceptibility to ACX-375 Analogues
Acurx Announces Results of Its Pioneering Research with Ibezapolstat in Collaboration with Leiden University Medical Center at the Premier International C. difficile Symposium
ACURX PHARMACEUTICALS ANNOUNCES PARTICIPATION AT THE H.C. Wainwright 26th Annual Global Investment Conference